RESUMO
The substantia nigra in Parkinson's disease (PD) is depleted of dopaminergic neurons and contains fibrillar Lewy bodies comprising primarily alpha-synuclein. We screened a library to identify drug-like molecules to probe the relation between neurodegeneration and alpha-synuclein fibrilization. All but one of 15 fibril inhibitors were catecholamines related to dopamine. The inhibitory activity of dopamine depended on its oxidative ligation to alpha-synuclein and was selective for the protofibril-to-fibril conversion, causing accumulation of the alpha-synuclein protofibril. Adduct formation provides an explanation for the dopaminergic selectivity of alpha-synuclein-associated neurotoxicity in PD and has implications for current and future PD therapeutic and diagnostic strategies.
Assuntos
Dopamina/metabolismo , Proteínas do Tecido Nervoso/química , Proteínas do Tecido Nervoso/metabolismo , Animais , Antioxidantes/farmacologia , Biopolímeros/química , Biopolímeros/metabolismo , Catecolaminas/farmacologia , Citoplasma/metabolismo , Dopamina/química , Dopamina/farmacologia , Humanos , Levodopa/farmacologia , Proteínas do Tecido Nervoso/genética , Proteínas do Tecido Nervoso/isolamento & purificação , Oxirredução , Estresse Oxidativo , Doença de Parkinson/etiologia , Doença de Parkinson/metabolismo , Doença de Parkinson/terapia , Quinonas/metabolismo , Espectrometria de Fluorescência , Vesículas Sinápticas/metabolismo , Sinucleínas , alfa-SinucleínaRESUMO
Fibrillar alpha-synuclein is a component of the Lewy body, the characteristic neuronal inclusion of the Parkinson's disease (PD) brain. Both alpha-synuclein mutations linked to autosomal dominant early-onset forms of PD promote the in vitro conversion of the natively unfolded protein into ordered prefibrillar oligomers, suggesting that these protofibrils, rather than the fibril itself, may induce cell death. We report here that protofibrils differ markedly from fibrils with respect to their interactions with synthetic membranes. Protofibrillar alpha-synuclein, in contrast to the monomeric and the fibrillar forms, binds synthetic vesicles very tightly via a beta-sheet-rich structure and transiently permeabilizes these vesicles. The destruction of vesicular membranes by protofibrillar alpha-synuclein was directly observed by atomic force microscopy. The possibility that the toxicity of alpha-synuclein fibrillization may derive from an oligomeric intermediate, rather than the fibril, has implications regarding the design of therapeutics for PD.
Assuntos
Proteínas do Tecido Nervoso/metabolismo , Doença de Parkinson/etiologia , Doença de Parkinson/metabolismo , Fosfolipídeos/metabolismo , Adsorção , Citotoxinas/metabolismo , Humanos , Corpos de Lewy/metabolismo , Proteínas do Tecido Nervoso/química , Proteínas do Tecido Nervoso/isolamento & purificação , Proteínas do Tecido Nervoso/toxicidade , Doença de Parkinson/terapia , Permeabilidade , Ácidos Fosfatídicos/metabolismo , Fosfatidilcolinas/metabolismo , Fosfatidilgliceróis/metabolismo , Ligação Proteica , Estrutura Secundária de Proteína , Sinucleínas , Fatores de Tempo , alfa-SinucleínaAssuntos
Peptídeos beta-Amiloides/química , Amiloide/química , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/fisiopatologia , Amiloide/genética , Peptídeos beta-Amiloides/genética , Escherichia coli/enzimologia , Doenças Genéticas Inatas/tratamento farmacológico , Humanos , Substâncias Macromoleculares , Dobramento de Proteína , Termodinâmica , beta-Galactosidase/química , beta-Galactosidase/genéticaRESUMO
Synthetic amyloid beta-protein (A beta) is used widely to study fibril formation and the physiologic effects of low molecular weight and fibrillar forms of the peptide on cells in culture or in experimental animals. Not infrequently, conflicting results have arisen in these studies, in part due to variation in the starting conformation and assembly state of A beta. To avoid these problems, we sought a simple, reliable means of preparing A beta for experimental use. We found that solvation of synthetic peptide with sodium hydroxide (A beta x NaOH), followed by lyophilization, produced stocks with superior solubility and fibrillogenesis characteristics. Solubilization of the pretreated material with neutral buffers resulted in a pH transition from approximately 10.5 to neutral, avoiding the isoelectric point of A beta (pI approximately 5.5), at which A beta precipitation and aggregation propensity are maximal. Relative to trifluoroacetate (A beta x TFA) or hydrochloric acid (A beta x HCl) salts of A beta, yields of "low molecular weight A beta" (monomers and/or dimers) were improved significantly by NaOH pretreatment. Time-dependent changes in circular dichroism spectra and Congo red dye-binding showed that A beta x NaOH formed fibrils more readily than did the other A beta preparations and that these fibrils were equally neurotoxic. NaOH pretreatment thus offers advantages for the preparation of A beta for biophysical and physiologic studies.
Assuntos
Peptídeos beta-Amiloides/síntese química , Fragmentos de Peptídeos/síntese química , Sequência de Aminoácidos , Peptídeos beta-Amiloides/química , Peptídeos beta-Amiloides/toxicidade , Animais , Células Cultivadas , Cromatografia Líquida de Alta Pressão , Dicroísmo Circular , Técnicas de Cocultura , Corantes , Vermelho Congo , Dimerização , Filtração , Liofilização , Humanos , Concentração de Íons de Hidrogênio , Ponto Isoelétrico , Microscopia de Força Atômica , Dados de Sequência Molecular , Peso Molecular , Neuroglia/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Fragmentos de Peptídeos/química , Fragmentos de Peptídeos/toxicidade , Conformação Proteica , Estrutura Secundária de Proteína , Ratos , Hidróxido de Sódio/farmacologia , Solubilidade , Solventes/farmacologia , Espectroscopia de Infravermelho com Transformada de Fourier , Relação Estrutura-Atividade , Fatores de TempoRESUMO
Parkinson's disease (PD) is a neurodegenerative disorder attributed to the loss of dopaminergic neurons from the substantia nigra. Some surviving neurons are characterized by cytoplasmic Lewy bodies, which contain fibrillar alpha-synuclein. Two mutants of human alpha-synuclein (A53T and A30P) have been linked to early-onset, familial PD. Oligomeric forms of these mutants accumulate more rapidly and/or persist for longer periods of time than oligomeric, human wild-type alpha-synuclein (WT), suggesting a link between oligomerization and cell death. The amino acid sequences of the mouse protein and WT differ at seven positions. Mouse alpha-synuclein, like A53T, contains a threonine residue at position 53. We have assessed the conformational properties and fibrillogenicity of the murine protein. Like WT and the two PD mutants, mouse alpha-synuclein adopts a "natively unfolded" or disordered structure. However, at elevated concentrations, the mouse protein forms amyloid fibrils more rapidly than WT, A53T, or A30P. The fibrillization of mouse alpha-synuclein is slowed by WT and A53T. Inhibition of fibrillization leads to the accumulation of nonfibrillar, potentially toxic oligomers. The results are relevant to the interpretation of the phenotypes of transgenic animal models of PD and suggest a novel approach for testing the cause and effect relationship between fibrillization and neurodegeneration.
Assuntos
Proteínas do Tecido Nervoso/antagonistas & inibidores , Proteínas do Tecido Nervoso/metabolismo , Precursores de Proteínas/antagonistas & inibidores , Precursores de Proteínas/metabolismo , Alanina/genética , Amiloide/química , Amiloide/metabolismo , Animais , Cromatografia em Gel , Humanos , Camundongos , Microscopia de Força Atômica , Mutagênese Sítio-Dirigida , Proteínas do Tecido Nervoso/genética , Proteínas do Tecido Nervoso/ultraestrutura , Doença de Parkinson/metabolismo , Conformação Proteica , Dobramento de Proteína , Precursores de Proteínas/genética , Precursores de Proteínas/ultraestrutura , Espectroscopia de Infravermelho com Transformada de Fourier , Sinucleínas , Treonina/genética , alfa-SinucleínaRESUMO
The first gene to be linked to Parkinson's disease encodes the neuronal protein alpha-synuclein. Recent mouse and Drosophila models of Parkinson's disease support a central role for the process of alpha-synuclein fibrillization in pathogenesis. However, some evidence indicates that the fibril itself may not be the pathogenic species. Our own biophysical studies suggest that a structured fibrillization intermediate or an alternatively assembled oligomer may be responsible for neuronal death. This speculation can now be experimentally tested in the animal models. Such experiments will have implications for the development of new therapies for Parkinson's disease and related neurodegenerative diseases.
Assuntos
Modelos Animais de Doenças , Ligases , Proteínas do Tecido Nervoso/metabolismo , Doença de Parkinson/etiologia , Doença de Parkinson/patologia , Ubiquitina-Proteína Ligases , Idade de Início , Animais , Predisposição Genética para Doença , Humanos , Doença de Huntington/genética , Doença de Huntington/patologia , Camundongos , Camundongos Knockout , Camundongos Transgênicos , Proteínas do Tecido Nervoso/genética , Doença de Parkinson/genética , Doença de Parkinson/terapia , Proteínas/genética , Sinucleínas , Tioléster Hidrolases/genética , Ubiquitina Tiolesterase , alfa-SinucleínaRESUMO
Two missense mutations in the gene encoding alpha-synuclein have been linked to rare, early-onset forms of Parkinson's disease (PD). These forms of PD, as well as the common idiopathic form, are characterized by the presence of cytoplasmic neuronal deposits, called Lewy bodies, in the affected region of the brain. Lewy bodies contain alpha-synuclein in a form that resembles fibrillar Abeta derived from Alzheimer's disease (AD) amyloid plaques. One of the mutant forms of alpha-synuclein (A53T) fibrillizes more rapidly in vitro than does the wild-type protein, suggesting that a correlation may exist between the rate of in vitro fibrillization and/or oligomerization and the progression of PD, analogous to the relationship between Abeta fibrillization in vitro and familial AD. In this paper, fibrils generated in vitro from alpha-synuclein, wild-type and both mutant forms, are shown to possess very similar features that are characteristic of amyloid fibrils, including a wound and predominantly unbranched morphology (demonstrated by atomic force and electron microscopies), distinctive dye-binding properties (Congo red and thioflavin T), and antiparallel beta-sheet structure (Fourier transform infrared spectroscopy and circular dichroism spectroscopy). alpha-Synuclein fibrils are relatively resistant to proteolysis, a property shared by fibrillar Abeta and the disease-associated fibrillar form of the prion protein. These data suggest that PD, like AD, is a brain amyloid disease that, unlike AD, is characterized by cytoplasmic amyloid (Lewy bodies). In addition to amyloid fibrils, a small oligomeric form of alpha-synuclein, which may be analogous to the Abeta protofibril, was observed prior to the appearance of fibrils. This species or a related one, rather than the fibril itself, may be responsible for neuronal death.
Assuntos
Amiloide/metabolismo , Mutação de Sentido Incorreto , Proteínas do Tecido Nervoso/genética , Proteínas do Tecido Nervoso/metabolismo , Doença de Parkinson/genética , Doença de Parkinson/metabolismo , Alanina/genética , Sequência de Aminoácidos , Amiloide/química , Amiloide/ultraestrutura , Benzotiazóis , Sítios de Ligação , Encéfalo/metabolismo , Encéfalo/patologia , Encéfalo/ultraestrutura , Dicroísmo Circular , Vermelho Congo , Endopeptidases/metabolismo , Humanos , Hidrólise , Imuno-Histoquímica , Corpos de Lewy/metabolismo , Corpos de Lewy/patologia , Corpos de Lewy/ultraestrutura , Microscopia de Força Atômica , Microscopia de Polarização , Dados de Sequência Molecular , Proteínas do Tecido Nervoso/biossíntese , Proteínas do Tecido Nervoso/ultraestrutura , Doença de Parkinson/patologia , Mudanças Depois da Morte , Prolina/genética , Estrutura Secundária de Proteína , Proteínas Recombinantes/biossíntese , Espectrometria de Fluorescência , Espectroscopia de Infravermelho com Transformada de Fourier , Sinucleínas , Tiazóis/metabolismo , Treonina/genética , alfa-SinucleínaRESUMO
Recent progress has improved our knowledge of how proteins form amyloid fibrils. Both 'natively unfolded' and globular proteins have been shown to initiate fibrillization by adopting a partially structured conformation. Oligomeric prefibrillar intermediates have been extensively characterized with respect to their morphology and temporal evolution. Three-dimensional models obtained using biophysical and computational methods have provided information about fibril structure. All of these advances suggest common features of self-assembly pathways, with subtle variations accounting for differences among distinct amyloid fibrils.
Assuntos
Amiloide/metabolismo , Dobramento de Proteína , Neuropatias Amiloides/metabolismo , Animais , Biopolímeros , Fenômenos Químicos , Físico-Química , Endopeptidases/fisiologia , Humanos , Proteínas do Tecido Nervoso/metabolismo , Conformação Proteica , Desnaturação Proteica , Difração de Raios XRESUMO
The rare neurological disorders frontotemporal dementia and British dementia have been linked to two mutant genes whose products constitute the fibrils that define the two disease pathologies. Two recent studies add to the mounting circumstantial case that protein fibrillization, inside (neurofibrillary tangles) or outside (amyloid plaques) of the neuron, may be pathogenic and suggest that either or both of these mechanisms could initiate Alzheimer's disease.
Assuntos
Corpos de Inclusão/patologia , Degeneração Neural/patologia , Sequência de Aminoácidos , Demência/genética , Demência/patologia , Humanos , Corpos de Inclusão/genética , Dados de Sequência Molecular , Degeneração Neural/genética , Emaranhados Neurofibrilares/genética , Emaranhados Neurofibrilares/patologiaRESUMO
The Parkinson's disease (PD) substantia nigra is characterized by the presence of Lewy bodies containing fibrillar alpha-synuclein. Early-onset PD has been linked to two point mutations in the gene that encodes alpha-synuclein, suggesting that disease may arise from accelerated fibrillization. However, the identity of the pathogenic species and its relationship to the alpha-synuclein fibril has not been elucidated. In this in vitro study, the rates of disappearance of monomeric alpha-synuclein and appearance of fibrillar alpha-synuclein were compared for the wild-type (WT) and two mutant proteins, as well as equimolar mixtures that may model the heterozygous PD patients. Whereas one of the mutant proteins (A53T) and an equimolar mixture of A53T and WT fibrillized more rapidly than WT alpha-synuclein, the other (A30P) and the corresponding equimolar mixture with WT fibrillized more slowly. However, under conditions that ultimately produced fibrils, the A30P monomer was consumed at a comparable rate or slightly more rapidly than the WT monomer, whereas A53T was consumed even more rapidly. The difference between these trends suggested the existence of nonfibrillar alpha-synuclein oligomers, some of which were separated from fibrillar and monomeric alpha-synuclein by sedimentation followed by gel-filtration chromatography. Spheres (range of heights: 2-6 nm), chains of spheres (protofibrils), and rings resembling circularized protofibrils (height: ca. 4 nm) were distinguished from fibrils (height: ca. 8 nm) by atomic force microscopy. Importantly, drug candidates that inhibit alpha-synuclein fibrillization but do not block its oligomerization could mimic the A30P mutation and thus may accelerate disease progression.
Assuntos
Proteínas do Tecido Nervoso/química , Doença de Parkinson/genética , Idade de Início , Substituição de Aminoácidos , Amiloide/química , Benzotiazóis , Cromatografia em Gel , Dicroísmo Circular , Fluorescência , Humanos , Microscopia de Força Atômica , Mutação , Proteínas do Tecido Nervoso/genética , Doença de Parkinson/etiologia , Doença de Parkinson/terapia , Conformação Proteica , Sinucleínas , Tiazóis , Ultracentrifugação , alfa-SinucleínaRESUMO
The yeast prion-like protein Sup35 has repeats responsible for the reversible induction of an altered, but advantageous phenotype. The expansion of similar repeat domains in several mammalian proteins is associated with neurodegenerative disease - so why are these 'bungee cord' domains conserved?
Assuntos
Proteínas Fúngicas/química , Príons/química , Proteínas de Saccharomyces cerevisiae , Saccharomyces cerevisiae/genética , Proteínas Fúngicas/fisiologia , Glutationa Peroxidase , Humanos , Proteína Huntingtina , Mutagênese Insercional , Proteínas do Tecido Nervoso/genética , Proteínas do Tecido Nervoso/metabolismo , Doenças Neurodegenerativas/genética , Doenças Neurodegenerativas/metabolismo , Proteínas Nucleares/genética , Proteínas Nucleares/metabolismo , Fragmentos de Peptídeos/fisiologia , Fatores de Terminação de Peptídeos , Peptídeos/metabolismo , Fenótipo , Proteínas PrPC/química , Proteínas PrPC/fisiologia , Proteínas PrPSc/química , Doenças Priônicas/genética , Doenças Priônicas/metabolismo , Príons/fisiologia , Conformação Proteica , Dobramento de Proteína , Estrutura Terciária de Proteína , Proteínas Recombinantes de Fusão/fisiologia , Sequências Repetitivas de Aminoácidos , Saccharomyces cerevisiae/química , Relação Estrutura-AtividadeAssuntos
Amiloide/genética , Amiloidose/genética , Encéfalo/patologia , Doenças Neurodegenerativas/genética , Doenças Neurodegenerativas/patologia , Doença de Alzheimer/genética , Doença de Alzheimer/metabolismo , Doença de Alzheimer/patologia , Peptídeos beta-Amiloides/genética , Amiloidose/metabolismo , Amiloidose/patologia , Encéfalo/metabolismo , Humanos , Mutação , Doenças Neurodegenerativas/metabolismo , Pré-Albumina/genéticaRESUMO
The definitive diagnosis of Alzheimer's disease (AD) requires the detection of amyloid plaques in postmortem brain. Although the amount of fibrillar amyloid roughly correlates with the severity of symptoms at the time of death, the temporal relationship between amyloid deposition, neuronal loss, and cognitive decline is unclear. To elucidate this relationship, a noninvasive, practical method for the quantitation of brain amyloid deposition is required. We describe herein the initial stages of a strategy to accomplish this goal by single photon computed tomographic imaging. The amyloid-binding dye Congo Red was modified to allow its conjugation to the monoamine-monoamide bis(thiol) ligand. This ligand complexes technetium(V) in its neutral oxo form. A biphenyl-containing building block was conjugated to the protected ligand, and the product was coupled to the relevant aromatic compounds. Rhenium oxo complexes, which are isosteric, but nonradioactive, analogues of the potential imaging agent technetium oxo complexes, were synthesized. These complexes bound to Abeta amyloid fibrils produced in vitro and stained amyloid plaques and vascular amyloid in AD brain sections.
Assuntos
Doença de Alzheimer/metabolismo , Peptídeos beta-Amiloides/metabolismo , Córtex Cerebral/metabolismo , Compostos Organometálicos/síntese química , Fragmentos de Peptídeos/metabolismo , Rênio , Corantes/metabolismo , Vermelho Congo/metabolismo , Humanos , Técnicas In Vitro , Compostos Organometálicos/metabolismo , Compostos de Organotecnécio/síntese química , Compostos de Organotecnécio/metabolismo , Compostos Radiofarmacêuticos/síntese química , Compostos Radiofarmacêuticos/metabolismo , Coloração e Rotulagem , Tomografia Computadorizada de Emissão de Fóton ÚnicoRESUMO
Amyloid fibrils comprising primarily the peptides A beta 40 and A beta 42 are a defining feature of the Alzheimer's disease (AD) brain, and convergent evidence suggests that the process of their formation plays a central role in the AD pathogenic pathway. Elucidation of fibril assembly is critical for the discovery of potential AD diagnostics and therapeutics, since the pathogenic entity is not necessarily the product fibril, but could be a precursor species whose formation is linked to fibrillogenesis in vivo. Atomic force microscopy allowed the identification of an unanticipated intermediate in in vitro fibril formation, the A beta amyloid protofibril. This manuscript describes studies of the structure of the A beta 40 protofibril and its in vitro assembly and disassembly using atomic force microscopy (AFM). The A beta 40 protofibril has a height of ca. 4.3 +/- 0.5 nm and a periodicity of ca. 20 +/- 4.7 nm. The rate of its elongation depends on the total concentration of A beta 40, the temperature, and ionic strength of the medium. A beta 42 and A beta 40 protofibrils elongate at a comparable rate. Statistical analysis of AFM data reveals a decrease in the number of protofibrils with time, indicating that coalescence of smaller protofibrils contributes to protofibril elongation. Similar analysis reveals that protofibrils shorten while the number of protofibrils also decrease following dilution, indicating that protofibril disassembly does not proceed by a reverse of the assembly process. These investigations provide systematic data defining factors affecting A beta fibrillization and, thus, should be valuable in the design of high-throughput assays to identify agents which alter A beta protofibril assembly.
Assuntos
Doença de Alzheimer/metabolismo , Peptídeos beta-Amiloides/química , Peptídeos beta-Amiloides/metabolismo , Modelos Biológicos , Adsorção , Doença de Alzheimer/etiologia , Doença de Alzheimer/patologia , Relação Dose-Resposta a Droga , Glicerol/química , Humanos , Concentração de Íons de Hidrogênio , Microscopia de Força Atômica/métodos , Elongação Traducional da Cadeia Peptídica/efeitos dos fármacos , Fragmentos de Peptídeos/química , Fragmentos de Peptídeos/metabolismo , Cloreto de Sódio/química , TemperaturaRESUMO
Transmissible spongiform encephalopathies (TSE) or prion diseases result in aberrant metabolism of prion protein (PrP) and the accumulation of a protease-resistant, insoluble, and possibly infectious form of PrP, PrP-res. Studies of PrP biosynthesis, intracellular trafficking, and degradation has been studied in a variety of tissue culture cells. Pulse-chase metabolic labeling studies in scrapie-infected cells indicated that PrP-res is made posttranslationally from an apparently normal protease-sensitive precursor, PrP-sen, after the latter reaches the cell surface. Cell-free reactions have provided evidence that PrP-res itself can induce the conversion of PrP-sen to PrP-res in a highly species- and strain-specific manner. These studies have shed light on the mechanism of PrP-res formation and suggest molecular bases for TSE species barrier effects and agent strain propagation.
Assuntos
Príons/análise , Animais , Técnicas de Cultura de Células/métodos , Sistema Livre de Células , Endopeptidases/metabolismo , Humanos , Métodos , Príons/metabolismoRESUMO
Two mutations in the gene encoding alpha-synuclein have been linked to early-onset Parkinson's disease (PD). alpha-Synuclein is a component of Lewy bodies, the fibrous cytoplasmic inclusions characteristic of nigral dopaminergic neurons in the PD brain. This connection between genetics and pathology suggests that the alpha-synuclein mutations may promote PD pathogenesis by accelerating Lewy body formation. To test this, we studied alpha-synuclein folding and aggregation in vitro, in the absence of other Lewy body-associated molecules. We demonstrate here that both mutant forms of alpha-synuclein (A53T and A30P) are, like wild-type alpha-synuclein (WT), disordered in dilute solution. However, at higher concentrations, Lewy body-like fibrils and discrete spherical assemblies are formed; most rapidly by A53T. Thus, mutation-induced acceleration of alpha-synuclein fibril formation may contribute to the early onset of familial PD.
Assuntos
Corpos de Lewy/ultraestrutura , Proteínas do Tecido Nervoso/química , Proteínas do Tecido Nervoso/genética , Neurônios/patologia , Doença de Parkinson/genética , Mutação Puntual , Idade de Início , Alanina , Substituição de Aminoácidos , Dicroísmo Circular , Humanos , Corpos de Lewy/patologia , Microscopia de Força Atômica , Microscopia Eletrônica , Mutagênese Sítio-Dirigida , Proteínas do Tecido Nervoso/ultraestrutura , Doença de Parkinson/patologia , Doença de Parkinson/fisiopatologia , Fosfoproteínas/genética , Proteínas Recombinantes/química , Proteínas Recombinantes/ultraestrutura , Substância Negra/patologia , Sinucleínas , Treonina , alfa-SinucleínaRESUMO
Ordered assembly of the amyloid-beta protein (A beta) into amyloid fibrils is a critical step in Alzheimer's disease (AD). To release the amyloidogenic peptide A beta from the Alzheimer amyloid precursor protein (APP), two secretases act sequentially: first, beta-secretase cleaves close to the membrane within the ectodomain and then gamma-secretase cuts within the transmembrane domain. The sites of gamma-secretase cleavage are after residues 40 or 42 of A beta. Except in those rare cases of AD caused by a mutation, levels of secreted A beta are not elevated; thus, the secretory pathway may be unaffected, and factors other than the extracellular concentration of A beta may contribute to the aggregation properties of the peptide. A beta is also present in intracellular compartments. The two gamma-secretase cleavage products, A beta42 and A beta40, were found in different compartments: A beta42 in the endoplasmic reticulum (ER)/intermediate compartment, and A beta40 in the trans-Golgi network (TGN). The cellular compartments that harbor A beta are target sites for therapeutic intervention. Here we report that in the brain, the principal compartment in which A beta resides is a detergent-insoluble glycolipid-enriched membrane domain (DIG). Also present in the DIG fractions are the endoproteolytic fragments of presenilin-1 (PS1) and APP. The presence of these proteins, which all contribute to the generation of A beta, indicates that the DIG fraction is probably where the intramembranous cleavage of APP occurs.